LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
LANDSCAPE
LANDSCAPE - Demographic Characteristics and Treatment Profiles of Patients Affected by Inflammatory Skin Diseases (Psoriasis, Atopic Dermatitis, Alopecia Areata, Vitiligo, Hidradenitis Suppurativa) in Italian Clinical Practice
1 other identifier
observational
20,000
1 country
1
Brief Summary
This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12 years and older with psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 30, 2025
CompletedStudy Start
First participant enrolled
January 1, 2026
CompletedFirst Posted
Study publicly available on registry
January 13, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2028
ExpectedJanuary 15, 2026
January 1, 2026
4 months
December 30, 2025
January 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Patient Distribution by Disease Type
Number and proportion of patients in each disease cohort (psoriasis, atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa).
January 2016 to December 2025
Age at Treatment Initiation
Mean age (years) at first systemic treatment initiation, reported by disease cohort.
January 2016 to December 2025
Sex Distribution
Proportion of male and female patients (percentage) by disease cohort.
January 2016 to December 2025
Secondary Outcomes (3)
Treatment Patterns and Therapeutic Sequences
January 2016 to December 2025
Disease Severity Assessment Over Time
January 2016 to December 2025
Treatment Persistence and Drug Survival
January 2016 to December 2025
Study Arms (5)
Psoriasis Cohort
Adult patients (≥18 years) diagnosed with moderate-to-severe psoriasis according to clinical criteria, treated with systemic conventional and/or biologic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
Atopic Dermatitis Cohort
Adult patients (≥18 years) diagnosed with moderate-to-severe atopic dermatitis, treated with systemic conventional and/or biologic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
Alopecia Areata Cohort
Adult patients (≥18 years) diagnosed with alopecia areata, treated with systemic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
Vitiligo Cohort
Adult patients (≥18 years) diagnosed with vitiligo, treated at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
Hidradenitis Suppurativa Cohort
Adult patients (≥18 years) diagnosed with hidradenitis suppurativa, treated with systemic conventional and/or biologic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records
Interventions
Retrospective observation of conventional systemic treatments prescribed in routine clinical practice, including but not limited to methotrexate, cyclosporine, acitretin, and other conventional agents. No drugs are administered as part of this study; treatment data are collected from existing medical records.
Retrospective observation of biologic treatments prescribed in routine clinical practice, including but not limited to TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-4/IL-13 inhibitors, and JAK inhibitors. No drugs are administered as part of this study; treatment data are collected from existing medical records.
Eligibility Criteria
Patients with inflammatory skin diseases (psoriasis, atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa) followed at approximately 25 dermatology centers across Italy. The study population reflects real-world clinical practice, including patients managed in both academic and community dermatology settings within the Italian National Health Service (Servizio Sanitario Nazionale). Data are extracted retrospectively from routine medical records.
You may qualify if:
- Documented diagnosis of psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.
- Age 12 years or older at the first recorded visit.
- Eligible for or treated with systemic therapies.
- At least one documented visit during January 2016 to December 2025.
- No opt-out exercised.
You may not qualify if:
- Opt-out exercised.
- Medical records with insufficient data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fondazione ISIDElead
Study Sites (1)
IRCCS Istituto Clinico Humanitas - Dermatology Unit
Rozzano, Lombardy, 20089, Italy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 30, 2025
First Posted
January 13, 2026
Study Start
January 1, 2026
Primary Completion
May 1, 2026
Study Completion (Estimated)
January 1, 2028
Last Updated
January 15, 2026
Record last verified: 2026-01